Metagenomi Therapeutics, Inc. (MGX) income statement
MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.56−0.05 (-7.95%)
Close on Nov 20, 2026Market cap $21.34MP/E –Yield –
Metagenomi Therapeutics, Inc. financial ratios
See a number that looks wrong?